Skip to content
Search

Latest Stories

Akshay Kumar says Sooryavanshi is a very relevant film

The trailer of Akshay Kumar starrer Sooryavanshi was released a few days ago. It has received a great response and moviegoers are eagerly waiting for the film.

In one of the sequences in the movie, Akshay is seen talking about Muslims in India. However, Akshay while talking to a news agency stated that the film’s story doesn’t view the world through the lens of religion. He said, “I don’t believe in any religion. I only believe in being Indian and that is what the film also shows. The idea of being an Indian and not about being a Parsi or a Hindu or a Muslim, we haven’t looked at it on the basis of the religion.”


When Akshay was asked if because of the current scenario in India, the film becomes relevant, the actor said, “It is a coincidence, we haven’t made it deliberately (now). But, yes, it is very much a relevant film today.”

This is for the first time when Akshay has worked with Rohit Shetty. While talking about his experience of collaborating with Shetty, Akshay said, “It was very easy to work with Rohit. I have known him for 28 years when he was an assistant and today he is the most notable director. We both love doing action and comedy, so it was fun. We finished the film in 55 to 60 days.”

Sooryavanshi also stars Katrina Kaif in the lead role and brings back the hit jodi of Akshay and Katrina on the big screen after a gap of a decade. Ranveer Singh and Ajay Devgn will be seen doing a cameo in the film, bringing all three cops of Rohit Shetty’s cop universe together.

The film was earlier slated to release on 27th March 2020, but it has been preponed and it will now hit the screens on 24th March 2020.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less